Madrigal Pharma (MDGL) Misses Q4 EPS by 44c

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($5.68), $0.44 worse than the analyst estimate of ($5.24).

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
• Cargojet Inc. (CJT:CN) (CGGJF) PT Raised to $128 at TD Cowen, maintains bullish call